Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

Potential vaccines for rheumatic fever researched

Trans-Tasman research collaboration to identify potential vaccines for rheumatic fever


The Health Research Council of New Zealand (HRC) has announced the funding of a trans-Tasman research coalition to accelerate the development of a vaccine against Group A Streptococcus (GAS) infection, which can cause rheumatic fever.

The governments of New Zealand and Australia have each committed initial funding of NZ$1.5 million over 18 months to support research to identify potential vaccines for GAS.

Rheumatic fever is a significant issue for Māori, Pacific Island, Australian Aboriginal and Torres Strait Islander communities. An effective vaccine would reduce the disease burden of rheumatic fever in these communities in Australia and New Zealand.

Rheumatic fever is a serious illness, which in New Zealand most often affects Māori and Pacific children and young adults, aged 4 to 19 years. It can lead to scarring of the heart valves and sometimes an early death in adults. The disease delivers a heavy burden on families, the community, and health services.

In February 2013, the Prime Minister of New Zealand, the Rt Hon. John Key, and the then Prime Minister of Australia, the Rt Hon. Julia Gillard, released a joint statement agreeing to jointly provide funding to support a trans-Tasman collaboration to identify potential vaccines for rheumatic fever.

The Australian National Health and Medical Research Council and the HRC have been given responsibility for overseeing this trans-Tasman initiative.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

The Coalition to Advance New Vaccines for Group A Streptococcus (CANVAS) led by Professor John Fraser at the University of Auckland and Professor Jonathan Carapetis in Australia, will evaluate and accelerate development of a preventive vaccine selected from three vaccines already in development overseas.

Health Minister Tony Ryall welcomes this collaboration that complements the Government’s existing investment to combat rheumatic fever, including the Rheumatic Fever Prevention Programme.

“Reducing rheumatic fever is a priority for the Government. We have invested more than $65 million over six years to combat this preventable illness, including supporting the development of a vaccine. This agreement shows just how seriously the Government is taking the fight against rheumatic fever,” he said.

ends

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.